Ductal carcinoma in situ of the breast: Current concepts and future directions

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 4, 2013, Pages 462-466

  Siziopikou, Kalliopi P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

BREAST TUMOR; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EPITHELIUM CELL; FEMALE; HUMAN; HYPERPLASIA; INTRADUCTAL CARCINOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; PAGET NIPPLE DISEASE; PATHOLOGY; REVIEW;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; HUMANS; HYPERPLASIA; MOLECULAR TARGETED THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 84876514784     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0078-RA     Document Type: Review

References (64)

1. SEER cancer statistics review. National Cancer Institute Web site. http://seer.cancer.gov. Accessed April 16, 2012.
2. Cancer facts and figures, 2008. American Cancer Society Web site. www.cancer.org. Accessed June 1, 2012.
3. Schnitt SJ, Silen W, Sadowsky NL, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med. 1988;318(14):898-903. (Pubitemid 18090275)
4. Lester SC, Bose S, Chen Y, et al; Cancer Committee of the College of American Pathologists. Protocol for the examination of specimens from patients with ductal carcinoma in situ (DCIS) of the breast. Arch Pathol Lab Med. 2009; 133(1):15-25.
5. Harris J, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast. 3rd ed. Lippincott Williams & Wilkins, Philadelphia, Pennsylvania. 2004.
6. Stomper PC, Margolin FR. Ductal carcinoma in situ: the mammographer's perspective. AJR Am J Roentgenol 1994;162(3):585-591. (Pubitemid 24093559)
7. Schnitt SJ, Collins LC. Biopsy interpretation of the breast. Biopsy Interpretation Series. Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, 2009 51-95.
8. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146-151. (Pubitemid 15192861)
9. Page DL, Dupont WD, Rodgers LW, Landenberger M. Intraductal carcinoma of the breast: follow up after biopsy only. Cancer. 1982;49(4):751- 758. (Pubitemid 12165434)
10. Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement: Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 1998; 122(12):1053-1055. (Pubitemid 29009396)
11. The Consensus Conference Committee. Consensus conference on the classification of ductal carcinoma in situ. Cancer. 1997;80 (9):1798-1802.
12. Bur ME, Zimarowski MJ, Schnitt SJ, et al. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer. 1992;69(5):1174-1181.
13. Bobrow LG, Happerfield LC, Bult P, et al. The classification of ductal carcinoma in situ and its association with biological markers. Sem Diagn Pathol. 1994;11(3):199-207. (Pubitemid 24308080)
14. Bose S, Lesser ML, Norton L, et al. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med. 1996;120(1):81-85. (Pubitemid 26021425)
15. Rudas M, Neumayer R, Gnant MF, et al. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer. 1997;33:39-44. (Pubitemid 27099565)
16. Mack L, Doig G, O'Malley FP. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erbB-2, bcl-2 and ki-67. Hum Pathol. 1997;28(8):974-979. (Pubitemid 27355559)
17. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319(19):1239-1245. (Pubitemid 18267063)
18. Bartkova J, Barnes DM, Millis RR, et al. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol. 1990;21(11):1164-1167. (Pubitemid 20382000)
19. Poller DN, Roberts EC, Bell JA, et al. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol. 1993;24(5):463-468. (Pubitemid 23145797)
20. O'Malley FP, Vnencak-Jones CL, Dupont WD. p53 mutations are confined to comedo type ductal carcinoma in situ of the breast: immunohistochemical and sequencing data. Lab Invest. 1994;71(1):67-72. (Pubitemid 24246023)
21. Guidi AJ, Fischer L, Harris JR, et al. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst. 1994;86(8):614-619. (Pubitemid 24143171)
22. Engels K, Fox SB, Whitehouse RM, et al. Distinct angiogenic patterns are associated with high grade in situ ductal carcinomas of the breast. J Pathol. 1997; 181(2):207-212. (Pubitemid 27087287)
23. Lagios MD, Westdahl PR, Margolin FR, et al. Duct carcinoma in situ: relationship of extent of non-invasive disease to the frequency of occult invasion, multicentricity, lymph node metastases and short-term treatment failures. Cancer. 1982;50(7):1309-1314. (Pubitemid 12031954)
24. Holland R, Hendriks JCL. Microcalcifications associated with ductal carcinoma in situ: mammographic-pathologic correlation. Semin Diagn Pathol. 1994;11(3):181-192. (Pubitemid 24308078)
25. Faverly DRG, Burgers L, Bult P, et al. Three dimentional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol. 1994;11(3):193-198. (Pubitemid 24308079)
26. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen year results of breast conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol. 1996;14(3):754-763. (Pubitemid 26085518)
27. Scott MA, Lagios MD, Axelsson K, et al. Ductal carcinoma in situ of the breast: reproducibility of histologic subtype analysis. Hum Pathol. 1997;28(8): 967-973. (Pubitemid 27355558)
28. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol. 1994;11(3):167-180. (Pubitemid 24308077)
29. European Commission Working Group on Breast Screening Pathology. Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. Hum Pathol. 1998; 29(10):1056-1062.
30. Dadmanesh F, Fan X, Dastane A, et al. Comparative analysis of size estimation by mapping and counting number of blocks with ductal carcinoma in situ in breast excision specimens. Arch Pathol Lab Med. 2009;133(1):26-30.
31. Page DL, Anderson TJ. Diagnostic Histopathology of the Breast. Churchill Livingstone, New York, New York, 1987.
32. Page DL, Dupont WD, Rogers LW, et al. Atypical hyperplastic lesions of the female breast: a long-term follow up study. Cancer. 1985;55(11):2698-2708. (Pubitemid 15092160)
33. Tavassoli FA, Norris HJ. A comparison of the results of long-term follow up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer. 1990;65(3):518-529. (Pubitemid 20058370)
34. Maluf HM. Differential diagnosis of solid carcinoma in situ. Semin Diagn Pathol. 2004;21(1):25-31. (Pubitemid 38327932)
35. Yaziji H, Gown AM, Sneige N. Detection of stromal invasion in breast cancer: the myoepithelial markers. Adv Anat Pathol. 2000;7(2):100-109.
36. Lerwill MF. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol. 2004;28 (8):1079-1091.
37. Sneige N, Wang J, Baker BA, et al. Clinical, histopathologic and biologic features of pleomorphic lobular (ductal-lobular) carcinomain situ of the breast: a report of 24 cases. Mod Pathol. 2002;15(10):1044-1050.
38. Jacobs JW. Recently recognized variants of lobular carcinoma in situ (LCIS) with an emphasis on management of LCIS on core needle biopsy. Pathol Case Rev. 2003;8(5):211-219.
39. Fulford LG, Reis-Filho JS, Lakhani SR. Lobular in situ neoplasia. Curr Diagn Pathol. 2004;10(3):183-192. (Pubitemid 38859632)
40. O'Sullivan MJ, Morrow M. Ductal carcinoma in situ-current management. Surg Clin North Am. 2007;87(2):333-351. (Pubitemid 46693951)
41. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16(2):441-452. (Pubitemid 28135585)
42. Fisher ER, Constantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17: intraductal carcinoma (ductal carcinoma in situ). Cancer. 1995;75(6):1310-1319.
43. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma in situ. Lancet. 1995;345(8958):1154-1157.
44. van Deurzen CH, Hobbelink MG, van Hillegersberg R, et al. Is there an indication for sentinel node biopsy in patients with ductal carcinoma in situ of the breast: a review. Eur J Cancer. 2007;43(6):993-1001. (Pubitemid 46483031)
45. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol. 2005;205(2):248-254.
46. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430-1441. (Pubitemid 38419997)
47. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, Marchio C, Reis-Filho JS. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57(2):171-192.
48. Allred DC, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP protocol B-24. Breast Cancer Res Treat. 2002;76(suppl 1):S36.
49. Lebeau A, Unholzer A, Amann G, et al. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2003;79(2):187- 198. (Pubitemid 36649168)
50. Siziopikou KP, Khan S. Correlation of HER2 gene amplification with expression of the apoptosis-suppressing genes bcl-2 and bcl-x-L in ductal carcinoma in situ of the breast. Appl Immunohistochem Mol Morphol. 2005; 13(1):14-18. (Pubitemid 40283797)
51. Cornfield DB, Palazzo JP, Schwartz GF, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer. 2004;100(11):2317-2327. (Pubitemid 38657878)
52. Provenzano E, Hopper JL, Giles GG, et al. Biological markers that predict recurrence in ductal carcinoma in situ of the breast. Eur J Cancer. 2003;39(5): 622-630. (Pubitemid 36287374)
53. Claus EB, Chu P, Howe CL, et al. Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol. 2001;70(3):303-316. (Pubitemid 32607203)
54. Perin T, Canzonieri V, Massarut S, et al. Immunohistochemical evaluation of multiple biological markers in ductal carcinoma of the breast. Eur J Cancer. 1996;32A(7):1148-1155. (Pubitemid 26231795)
55. Ramachandra S, Machin L, Ashley S, et al. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma - a detailed morphological analysis. J Pathol. 1990;161(1):7-14. (Pubitemid 20173376)
56. Bobrow LG, Happerfield LC, Gregory WM, et al. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol. 1995;176(4):333-341.
57. Leal CB, Schmitt FC, Bento MJ, et al. Ductal carcinoma in situ of the breast: histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer. 1995;75(8): 2123-2131.
58. Livasy CA, Perou CM, Karaca G, et al. Identification of basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007;38 (2):197-204. (Pubitemid 46096566)
59. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol. 2006;19(5):617-621.
60. Fisher B, Dignam J, Wickerham DL, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet. 1999;353 (9169):1993-2000. (Pubitemid 29271743)
61. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344 (11):783-792. (Pubitemid 32222155)
62. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17(9):2639-2648. (Pubitemid 29415219)
63. Julian JB, Anderson SJ, Cobleigh MA, et al. A phase III clinical trial comparing trastuzumab given concurrently with radiation therapy to radiation therapy alone for women with HER2-positive DCIS resected by lumpectomy: NSABP B-43. Cancer Res. 2011;71(24 suppl): 603s.
64. Kuerer HM, Buzdar AU, Mittendorf EA, et al. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011;117(1):39-47.